In clinical liver transplantation, a venous bypass that rechannels the blood flow from the inferior vena cava and portal vein to the superior vena cava has been used to maintain the venous return. However, the usage of mechanical shunt has given rise to derangements of blood coagulability and fibrinolysis. Therefore, changes of coagulability and fibrinolysis during the venous bypass were examined in dogs using a centrifugal pump (Bio-Pump®), and the effect of gabexate mesilate for coagulation were studied. Venous bypass from the inferior vena cava and the portal vein to the external jugular vein was performed in mongrel dogs (group A : bypass without pump, group B : bypass with the Bio-Pump, group C : bypass with the Bio-Pump and the addition of gabexate mesilate). In group A, blood pressure gradually decreased, but in groups B and C it maintained the pre-bypass level. All results of coagulation parameters and fibrinolytic measurements of group B were not significantly different from those of group A ; only partial thromboplastin time was prolonged in group B. However, this prolongation was effectively prevented by the addition of gabexate mesilate in group C.
endostage hepatic disease and preexisting coagulation defect (Starzl et al. 1982) . Therefore, the pump-driven veno-venous bypass is usually used without systemic heparinization.
The use of a pump-driven veno-venous bypass without systemic heparinization disarranged blood coagulability and results in the formation of clot in the shunt tube, and develops emboli in the lung.
We examined, the coagulability and fibrinolysis in the pump driven venovenous bypass using dogs. The effect of gabexate mesilate (FOYR ), which has an anticoagulant effect (Ohno et al. 1980 ) and is used in hemodialysis, was also studied.
MATERIALS AND METHODS
The bypass cannulation from the inferior vena cava and the portal vein to the external jugular vein was performed on healthy mongrel dogs, weighing from 10 to 20 kg. General anesthesia was induced with thiopental (30 mg kg) and maintained with oxygen and halothan.
As shown in Fig. 1 , the inferior vena cava above the right adrenal vein, the suprahepatic vena cava, the portal vein and the hepatic artery were cross-clamped and the venovenous tube bypass made of a polyvinylchloride was used in Group A. In Group B, a veno-venous bypass with the Bio-pump was utilized. Group C, a pump-driven verso-venous bypass was employed together with the administration of gabexate mesilate (5 pg ml). In each group, 4 mongrel dogs were used for study. No heparin was administered systemically or in the bypass tube.
During both the passive and the pump-driven veno-venous bypass the blood pressure was continuously recorded. The blood flow of the inferior vena cava, the portal vein and the bypass tube was measured. Measurements of blood coagulability and fibrionolysis were made prior to the cross-clamp and at 30, 60 and 90 min after the occlusion.
Red blood cells, white blood cells and platelets were measured. For evaluation of the coagulability and fibrinolysis, prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen, CY2-plasminogen inhibitor (a2PI), anti-thrombin III (AT III), and plasminogen (PLG) were investigated (Ohkohchi et al. 1986 ). Microscopical findings of the lung were examined after 90 min veno-venous bypass. The results were presented as mean ± SE. Statistical analysis was done using the Student's t-test.
RESULTS

Blood flow
In 12 healthy dogs, the blood flow of the inferior vena cava was 26.6+2.2 ml/ kg/min and the portal vein flow was 29.4± 2.1 ml/kg/min. In the passive bypass group, Group A, the bypass flow ranged from 200 to 300 ml/min, with the mean of 20.5±4.4 ml/kg/min at the beginning and gradually decreased. In the pumpdriven bypass groups, Groups B and C, the flow ranged from 300 to 600 ml/min, with the mean of 36.0± 8.7 ml/kg/min. In groups B and C, when an attempt was made to keep the flow over 50 ml/kg/min, the sucking power was too strong to maintain a steady flow. Blood pressure The mean blood pressure and pulse pressures decreased gradually in Group A. In groups B and C, the blood pressure fell at the time of the cross clamping, however, it recovered immediately after the pump began to operate and there was no significant change until 90 min later.
Clot formation
Many clots were seen inside the tube in Group A. In Group B, a few clots were observed in portions of the bypass tube. No clots were seen in Group C.
Peripheral blood cell
Red blood cells did not decrease nor hemolyze in any group. However, white blood cells and platelets decreased significantly at 30 min in each group (Table 1 , Fig. 2 ). There was no significant difference at every time among these groups during the bypass.
Coagulability and fibrinolysis
During bypass, significant prolongation of PT was noted in each group at 60 and 90 min (p <0.05). As shows in Fig. 3 , PTT was prolonged significantly after 30 min in every group (p <0.05). Among these groups, a minimal change in PTT was seen in Group C and the prolongation at 90 min was effectively depressed by gabexate mesilate (p <0.05). The value of fibrinogen, a2PI, AT III and PLG significantly decreased after 30 min (p <0.05) in each group and reached to about 70 to 80% of the pre-bypass values. However, there was no significant difference among these groups at every time during the bypass.
DISCUSSION
When the native liver has been removed, cross clamping of the portal vein and the inferior vena cava caused several problems, for instance, the loss of blood return to the central venous system from the abdomen, and hyperkalemia caused by stagnant blood from the obstructed venous beds at revascularization. Shaw et al. (1984) reported that during anhepatic phase, the mean arterial pressure, central venous pressure and pulmonary artery wedge pressure were maintatined at prehepatectomy levels using a pump-driven veno-venous bypass without systemic heparinization.
This method reduced operative blood loss and the frequency of postoperative renal failure and increased the probability of survival. However, clots sometimes formed in the bypass tube and caused emboli of the lung. In this study we examined the change of the coagulability and fibrinolysis during the bypass and the effect of gabexate mesilate on the disarrangement of the coagulability. This study shows that the pump-driven veno-venous bypass without heparinization can retain sufficient flow to keep the blood pressure stable during anhepatic phase. During the pump-driven bypass, PT and PTT prolonged and AT III, PLG, Fibrinogen and APL decreased. These disarrangements of the coagulability and fibrinolysis might be caused by blood contact with the inner surface of the bypass tube and stiring by the pump. In groups A and B, the clots were visible on the inner wall of the bypass tube. There was no significant difference, however, in the data between the pump-driven bypass and the passive bypass. These results show that the Bio-pump activates the coagulation and fibrinolysis slightly, the same as the passive bypass.
Gabexate mesilate, an inhibitor of the proteolytic enzyme, prevented the clot formation and the prolongation of PTT. Therefore, the administration of gabexate mesilate to the pump-driven veno-venous bypass is effective in preventing coagulation.
White blood cell and platelet counts decreased significantly during the bypass in each group. In microscopical study, there was no pathological finding in the lung. The results suggests that these components might adhere to the inner surface of the bypass tube (Nakao et al. 1986 ).
In summary, the pump-driven veno-venous bypass stabilized the systemic circulation during the anhepatic phase, and the changes in coagulability and fibrinolysis were slight during the bypass. However, blood components, for instance, white blood cells and platelets, might adhere to inside of the bypass tube. Therefore, a further study for a more suitable material for the bypass tube is neccesary.
